NewsEvents

Your Yourlocation: Home > Effects of tiotropium bromide(136310-93-5) on lung function and inflammatory cytokines in patients with moderate to severe stable chronic obstructive pulmonary disease

To observe the clinical efficacy of tiotropium bromide(136310-93-5) in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). The study indicates that tiotropium improves lung function in COPD patients, reduces inflammatory factor levels, and improves treatment outcomes. The article published on 2015 fifteenth issue of "Journal of Practical Clinical Medicine".

88 patients with COPD were randomly divided into observation group and control group, 44 cases. In the control group, routine treatment, the observation group in the control group on the basis of increased inhalation of tiotropium bromide(136310-93-5) powder. The clinical curative effect and the change of blood gas analysis index, lung function index and inflammatory factor before and after treatment were compared.

The total effective rate of the observation group was 93.18% (41/44), which was significantly higher than that of the control group (77.27%, 34/44). The difference was significant (P <0.05). After the treatment, the arterial oxygen partial pressure [p (O2)], forced vital capacity (FVC), forced expiratory volume per minute (FEV1) and FEV1 / FVC ratio in the two groups were significantly increased (P <0.01) (P <0.01). The carbon dioxide partial pressure [p (CO2)] of the two groups was significantly lower than that of the control group (P <0.01). After treatment, the levels of IL-6, hs-CRP and TNF-α in the two groups were significantly lower than those before treatment (P <0.01), and the levels of IL-6, hs-CRP and TNF- And the decrease of the observation group was greater than that of the control group (P <0.01).

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved